DeepMed Research

Carboxymethylcellulose

Generic Name: Carboxymethylcellulose

Brand Names: Leader Lubricant Eye Drops, Refresh Drops, Refresh Liquigel, Refresh Optive Advanced, Refresh Optive Extended Therapy, Retaine, Thera Tears, Theratears

Drug Type: Small Molecule

CAS Number: 9000-11-7

Unique Ingredient Identifier: 05JZI7B19X

Background: Carboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. It is added in food products as a viscosity modifier or thickener and emulsifier. It is also one of the most common viscous polymers used in artificial tears, and has shown to be effective in the treatment of aqueous tear-deficient dry eye symptoms and ocular surface staining . The viscous and mucoadhesive properties as well as its anionic charge allow prolonged retention time in the ocular surface . Sodium carboxymethylcellulose is the most commonly used salt.

Indication: Indicated for the symptomatic relief of burning, irritation and discomfort of the eyes due to dryness or exposure to wind or sun.

Associated Conditions: Dry Eyes, Ocular Irritation

Clinical Trials

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

Phase 4

Completed

Conditions: Dry Eye Syndromes
Keratoconjunctivitis Sicca

Interventions: Drug: carboxymethylcellulose 0.5%/glycerin 0.9%
Drug: sodium hyaluronate 0.18%

First Posted Date: 2014-04-21

Last Posted Date: 2019-04-18

Lead Sponsor: Allergan

Target Recruit Count: 80

Registration Number: NCT02117687

A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms

Phase 4

Completed

Conditions: Cataract
Dry Eye Syndromes

Interventions: Drug: Sodium Carboxymethylcellulose
Drug: Levofloxacin
Drug: Prednisolone

First Posted Date: 2014-01-07

Last Posted Date: 2014-04-23

Lead Sponsor: Allergan

Target Recruit Count: 180

Registration Number: NCT02028754

A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN)

Phase 4

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: TheraTears® Lubricant Eye Drop
Drug: TheraTears® preservative-free single-use containers
Dietary Supplement: TheraTears® Nutrition
Other: TheraTears® TheraLid® Eyelid Cleanser

First Posted Date: 2013-12-18

Last Posted Date: 2015-03-11

Lead Sponsor: University of Waterloo

Target Recruit Count: 33

Registration Number: NCT02014922

Locations: 🇨🇦
Centre for Contact Lens Research, University of Waterloo School of Optometry & Vision Science, Waterloo, Ontario, Canada

A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery

Phase 3

Completed

Conditions: Bilateral LASIK Surgery

Interventions: Drug: carboxymethylcellulose sodium based eye drops
Drug: carboxymethylcellulose sodium based new eye drop formulation

First Posted Date: 2013-06-26

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 148

Registration Number: NCT01886690

A Study to Compare a New Eye Drop Formulation With Refresh Contacts®

Phase 3

Completed

Conditions: Contact Lens Lubrication

Interventions: Drug: carboxymethylcellulose based eye drop formula
Drug: carboxymethylcellulose sodium based eye drop solution

First Posted Date: 2013-05-01

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 365

Registration Number: NCT01844388

A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A
Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops

First Posted Date: 2012-08-14

Last Posted Date: 2015-09-21

Lead Sponsor: Allergan

Target Recruit Count: 460

Registration Number: NCT01664949

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A
Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
Drug: Carboxymethylcellulose Based Lubricant Eye Drops
Drug: Carboxymethylcellulose Based Eye Drop Formulation B

First Posted Date: 2011-10-25

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 315

Registration Number: NCT01459588

Efficacy of the Chronic Application of Tear Formulations

Not Applicable

Conditions: Dry Eye

Interventions: Drug: Next Generation Emulsion
Drug: Refresh Dry Eye Therapy
Drug: Refresh Contacts

First Posted Date: 2011-06-29

Last Posted Date: 2011-07-01

Lead Sponsor: Glasgow Caledonian University

Target Recruit Count: 38

Registration Number: NCT01384851

Locations: 🇬🇧
Glasgow Caledonian University, Glasgow, United Kingdom

Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms

Phase 4

Conditions: Dry Eye Syndromes

Interventions: Drug: Altaire Gel forming solution
Drug: Refresh Tears

First Posted Date: 2011-06-27

Last Posted Date: 2012-06-14

Lead Sponsor: Innovative Medical

Target Recruit Count: 100

Registration Number: NCT01382810

Locations: 🇺🇸
Koch Eye Associates, Warwick, Rhode Island, United States
🇺🇸
Jackson Eye, SC, Lake Villa, Illinois, United States

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: carboxymethylcellulose sodium based New Eye Drop Formulation 2
Drug: carboxymethylcellulose sodium based Eye Drops
Drug: carboxymethylcellulose sodium based New Eye Drop Formulation 1

First Posted Date: 2011-02-11

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 305

Registration Number: NCT01294384

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy